Premium
Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine
Author(s) -
Schröder O.,
Blumenstein I.,
SchulteBockholt A.,
Stein J.
Publication year - 2004
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2004.01850.x
Subject(s) - medicine , infliximab , azathioprine , methotrexate , crohn's disease , surgery , gastroenterology , disease
Summary Background : Crohn's disease is complicated by fistulas in 20–40% of patients at some time during the course of their illness. Azathioprine has been reported to heal fistulas in 30–40% of cases. Long‐lasting effects by the anti‐tumour necrosis factor‐α antibody infliximab most often require repeated infusions. Methotrexate has been shown to be an effective drug in maintaining remission in Crohn's disease. Aim : To evaluate the combination of infliximab and methotrexate as therapy for fistulas in patients with Crohn's disease. Methods : Twelve consecutive patients (mean age, 29.5 years) with fistulizing Crohn's disease resistant or intolerant to azathioprine were followed prospectively. Patients received three infusions of infliximab (5 mg/kg) and long‐term methotrexate (20 mg/week). Therapy success was defined as sustained closure of fistulas ≥ 6 months after fistula closure. Results : In four of the 12 patients, complete closure of fistulas that persisted for ≥ 6 months (median follow‐up, 13.25 months) was observed. In three further patients, a partial response was noted. In five patients, persistent therapy success could not be achieved or therapy had to be stopped due to side‐effects. Conclusions : A combination of infliximab with long‐term methotrexate may be a promising concept in fistulizing Crohn's disease. Our data indicate the need for larger controlled trials.